Oxford BioMedica PLC (OXBDF)

[marcusl2]

An experienced biotech investor, Loncar created the Loncar Immunotherapy Index, a collection of 30 life science companies with five large-cap and 25 growth stocks. He said the advisory committee will need to make a very human calculation. "It must be noted that the patients being treated in these studies are very sick and likely facing certain death so there is a risk/reward trade-off the FDA will have to consider."

In an investor note Loncar said, "I predict that both Novartis and Kite will earn approval in the coming months, and this will be an inflection point for cellular therapies. This unique method of treating cancer is very special and has the potential to revolutionize the treatment of many cancers in the future